Resources

Sanofi and Lexicon to continue any required studies in effort to move sotagliflozin forward.

Dapagliflozin’s updated package insert confirms efficacy and safety profile for patients with moderate chronic kidney disease.

Paula Trief, PhD received her PhD in Clinical Psychology from Syracuse University. She joined the faculty at SUNY Upstate Medical University in the Department of Psychiatry & Behavioral Sciences in 1993. She is currently a tenured Distinguished Service Professor of Psychiatry & Behavioral Sciences, with joint appointments in the departments of Medicine and Orthopedic Surgery. Academically, she is an active behavioral science researcher, studying behavioral interventions for patients with diabetes. Her current RO1 studies factors that predict medication adherence and healthcare usage in emerging adults with type 2 diabetes.

Clinical utility of T1DM susceptibility genes: One of the goals of genetic studies of complex disease is to identify a profile of susceptibility variants that can be used to predict an individual’s risk of developing a given disease. The long prodrome for T1DM, characterized by progressive loss of beta-cell mass, provides an attractive opportunity for intervention to prevent disease development if “at-risk” individuals can be identified. Currently the best markers of disease risk are a positive family history of T1DM and the presence of autoantibodies to islet cell proteins. Over 90% of T1DM patients have no affected relatives, however, so effective preventive efforts will need to target the general population. Unfortunately screening such huge numbers of individuals for islet autoantibodies is logistically unfeasible, particularly given the need for repeated annual testing for those with a negative result. Genetic markers are therefore needed to stratify risk in the general population,

In this Exclusive Interview transcript, psychologist Paula Trief talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the role of mental health in diabetes and how partners of people with diabetes can be of support in diabetes care.

In this Exclusive Interview, psychologist Paula Trief talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about how partners of people with diabetes can be of support in diabetes care.

In part 1 of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about ways the partners of people with diabetes can be of help.

In part 2 of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about the importance of communication between partners who are living with an ongoing health condition such as diabetes.

In part 3 of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about the results of a couples intervention trial, the Diabetes Support Project.

In part 4 of this Exclusive Interview, Paula Trief talks with Diabetes in Control Publisher Steve Freed about the importance of education for the partner of a person with diabetes, among other things they can do to be of support.